EU Approves Novo Nordisk's Frehemgo for Hemophilia A
The European Commission granted marketing authorization for the prophylaxis treatment, which is dosed monthly, biweekly, or weekly via a prefilled pen.
Updated on Nov. 13, 2026 in Diabetes
The European Commission has granted marketing authorization for Novo Nordisk's Frehemgo, approved for routine prophylaxis to prevent or reduce bleeding episodes in patients with hemophilia A. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Why it matters
The approval adds a routine prophylaxis option for people living with hemophilia A in the European Union. The product has also been approved in Saudi Arabia and remains under review by the U.S. Food and Drug Administration and other regulators.
The approval rests on a positive opinion issued by the Committee for Medicinal Products for Human Use in September, with the Commission's authorization announced November 13, 2026. Dosing options range from once monthly to once weekly, and the source does not report comparative efficacy figures.
The players
Novo Nordisk
Novo Nordisk is a Danish pharmaceutical company known for its diabetes and rare blood disorder treatments, including insulin and hemophilia therapies.
The details
Frehemgo is administered with a single-use prefilled pen and is intended to prevent or reduce bleeding episodes in hemophilia A patients. Novo Nordisk announced the European Commission's authorization, and the product is also approved in Saudi Arabia while under review by the U.S. Food and Drug Administration and other regulators.
Timeline
September: The Committee for Medicinal Products for Human Use issued a positive opinion for Frehemgo.
November 13, 2026: The European Commission granted marketing authorization, announced by Novo Nordisk.
Health Landscape
Frehemgo's approval follows the European Medicines Agency's centralized marketing authorization procedure, which grants a single EU-wide approval for new medicines. It adds to a growing set of prophylactic options for hemophilia A, a category long dominated by factor replacement therapies.
For people with hemophilia A in the European Union, Frehemgo offers a prefilled-pen option that can be dosed monthly, every two weeks, or weekly to prevent bleeding episodes. Availability and reimbursement will depend on national decisions, which the source does not address.
The takeaway
Routine prophylaxis can be dosed on schedules ranging from monthly to weekly, giving patients and clinicians flexibility in managing hemophilia A. Patients should consult their treating clinicians about whether a prophylaxis option fits their care plan.
Further reading
For related coverage of blood sugar and metabolic conditions treated by the same manufacturer, see Diabetes.
